A comprehensive view of Horizon Therapeutics Plc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Amgen to lay off 350 workers at Horizon Therapeutics following their US$27.8B acquisition of the company; Amgen assures job placement for 80% of Horizon's workforce and supportive transition for those affected
Published: October 24, 2023 by Chicago Tribune (IL)
Leerink upgrades Amgen to outperform, citing promising pipeline developments and recent acquisition of Horizon Therapeutics; substantial earnings boost also expected, as well as multiple market opportunities in obesity, inflammation and oncology sectors
Published: October 18, 2023 by Zacks Investment Research
Amgen completes Horizon Therapeutics buyout for US$27.8B; Horizon's Tepezza, Krystexxa and Uplizna expected to enhance Amgen’s autoimmune portfolio
Published: October 06, 2023 by FiercePharma
Amgen and Horizon Therapeutics reach a consent order agreement with the FTC, resolving an administrative lawsuit and clearing the way for Amgen’s acquisition of Horizon; the acquisition is expected to finalize early in Q4 2023
Published: September 01, 2023 by Business Wire
FTC pauses legal proceedings to block Amgen's proposed takeover of Horizon Therapeutics, mulling potential settlement; possible resolution is under consideration until Sept. 18
Published: August 28, 2023 by FiercePharma

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count